Galle P et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology front wo randomised, placebo-controlled phase 3 studies (REACH-2 and REACH). (Abstract GS-09)
ACE2-spiegel verklaart mogelijk hoger COVID-19-risico bij mannen
mei 2020 | Pneumonie, Virale infecties